Loading…
Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus
Influenza virus remains a continuous and severe threat to public health worldwide, and its prevention and treatment have always been a major international issue. Because of its ability to evade immune surveillance through rapid antigenic drift and antigenic shift, broad-spectrum vaccines seem increa...
Saved in:
Published in: | Virology journal 2020-12, Vol.17 (1), p.191-191, Article 191 |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c548t-aab71f54b330af94ddd73775beec4d289ce328c5ed1a63379572a747c8b22f253 |
container_end_page | 191 |
container_issue | 1 |
container_start_page | 191 |
container_title | Virology journal |
container_volume | 17 |
creator | Huang, Jingjin Huang, Nan Fan, Menglu Zhao, Lingcai Luo, Yan Ding, Pingyun Tian, Miao Liu, Qingzheng Guo, Yanna Zhao, Jinhua Zheng, Yiqing Zhang, Haitao Ping, Jihui |
description | Influenza virus remains a continuous and severe threat to public health worldwide, and its prevention and treatment have always been a major international issue. Because of its ability to evade immune surveillance through rapid antigenic drift and antigenic shift, broad-spectrum vaccines seem increasingly important.
A mAb named 3C12 from an immortalized hybrid cell was generated via immunizing mice with HA2 protein from A/chicken/Anhui/BRI99/2016 (AH/BRI99/16, H9N2) generated by prokaryotic expression. Then, its broad-spectrum activity was analyzed by WB and IFA. Next, the minimal linear epitope was identified via analyzing the reaction of a series of HA truncations with 3C12. Finally, the protective effects of 3C12 were evaluated in vitro and in vivo infection experiments.
The mAb could react with the viruses of subtypes H1, H2, H5, H8, H9, H12, H13, H16, and HA protein of H18 in group 1, but failed to react with viruses in group 2. The minimal linear epitope targeted by the mAb was
NAELLVL
in full length of HA and localized in the C-helix region of HA2 (residue 95-101, HA2 numbering). What's more, the mAb 3C12 inhibited H1, H2, H5, H8, H9, H12, H13 and H16 virus-replication in vitro and also has shown effectiveness in preventing and treating disease in mice challenged with lethal dose of AH/BRI99/16 (H9N2) virus in vivo. These results suggested that the broadly reactive anti-HA stem mAb 3C12 exhibited prophylactic and therapeutic efficacy.
Here, we have demonstrated that the linear epitope identified in this study could be a novel target for developing broad-spectrum influenza diagnostics or vaccine design, and the HA2-based monoclonal antibody is indeed a promising strategy for broad-spectrum protection against seasonal and pandemic influenza viruses. |
doi_str_mv | 10.1186/s12985-020-01458-z |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_50bded29466f463aa6406f3f72330a00</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A650619281</galeid><doaj_id>oai_doaj_org_article_50bded29466f463aa6406f3f72330a00</doaj_id><sourcerecordid>A650619281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c548t-aab71f54b330af94ddd73775beec4d289ce328c5ed1a63379572a747c8b22f253</originalsourceid><addsrcrecordid>eNptkl2L1DAUhoso7jr6B7yQgjd60TVfTdobYVjUHVgQ_ADvwmmS1oxpMybp4MyvN7OzrjsiuUg4ec57kpe3KJ5jdIFxw99ETNqmrhBBFcKsbqr9g-IcC0YrRsi3h_fOZ8WTGNcIUcJF-7g4o5Q0omHtebG-MiMMg5uTnexUxgTuR9VBNLoc_eSV8xO4EqZkO693pXFW2RTLLnjQblcGAyrZrU27EgawU0zlEPy8KXFpp97NZtpDuSy3NszxafGoBxfNs9t9UXx9_-7L5VV1_fHD6nJ5XamaNakC6ATua9ZRiqBvmdZaUCHqzhjFNGlaZfLrVW00Bk6paGtBQDChmo6QntR0UayOutrDWm6CHSHspAcrbwo-DBJCssoZWaNOG01axnnPOAXgDPGe9oIchme_FsXbo9Zm7kajlZlSAHcienoz2e9y8FspBEGIHx7z6lYg-J-ziUmONirjHEzGz1ESxhtKeWYz-vIfdO3nkO0_UAITjNum-UsNkD-QTfZ5rjqIyiWvEcctaXCmLv5D5aXNaJWfTG9z_aTh9UlDZpL5lQaYY5Srz59OWXJkVfAxBtPf-YGRPCRTHpMpczLlTTLlPje9uO_kXcufKNLf1E3eeA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471211988</pqid></control><display><type>article</type><title>Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Huang, Jingjin ; Huang, Nan ; Fan, Menglu ; Zhao, Lingcai ; Luo, Yan ; Ding, Pingyun ; Tian, Miao ; Liu, Qingzheng ; Guo, Yanna ; Zhao, Jinhua ; Zheng, Yiqing ; Zhang, Haitao ; Ping, Jihui</creator><creatorcontrib>Huang, Jingjin ; Huang, Nan ; Fan, Menglu ; Zhao, Lingcai ; Luo, Yan ; Ding, Pingyun ; Tian, Miao ; Liu, Qingzheng ; Guo, Yanna ; Zhao, Jinhua ; Zheng, Yiqing ; Zhang, Haitao ; Ping, Jihui</creatorcontrib><description>Influenza virus remains a continuous and severe threat to public health worldwide, and its prevention and treatment have always been a major international issue. Because of its ability to evade immune surveillance through rapid antigenic drift and antigenic shift, broad-spectrum vaccines seem increasingly important.
A mAb named 3C12 from an immortalized hybrid cell was generated via immunizing mice with HA2 protein from A/chicken/Anhui/BRI99/2016 (AH/BRI99/16, H9N2) generated by prokaryotic expression. Then, its broad-spectrum activity was analyzed by WB and IFA. Next, the minimal linear epitope was identified via analyzing the reaction of a series of HA truncations with 3C12. Finally, the protective effects of 3C12 were evaluated in vitro and in vivo infection experiments.
The mAb could react with the viruses of subtypes H1, H2, H5, H8, H9, H12, H13, H16, and HA protein of H18 in group 1, but failed to react with viruses in group 2. The minimal linear epitope targeted by the mAb was
NAELLVL
in full length of HA and localized in the C-helix region of HA2 (residue 95-101, HA2 numbering). What's more, the mAb 3C12 inhibited H1, H2, H5, H8, H9, H12, H13 and H16 virus-replication in vitro and also has shown effectiveness in preventing and treating disease in mice challenged with lethal dose of AH/BRI99/16 (H9N2) virus in vivo. These results suggested that the broadly reactive anti-HA stem mAb 3C12 exhibited prophylactic and therapeutic efficacy.
Here, we have demonstrated that the linear epitope identified in this study could be a novel target for developing broad-spectrum influenza diagnostics or vaccine design, and the HA2-based monoclonal antibody is indeed a promising strategy for broad-spectrum protection against seasonal and pandemic influenza viruses.</description><identifier>ISSN: 1743-422X</identifier><identifier>EISSN: 1743-422X</identifier><identifier>DOI: 10.1186/s12985-020-01458-z</identifier><identifier>PMID: 33287849</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Antigenic drift ; Avian flu ; Broad-spectrum ; Epitope ; Epitopes ; Genetic aspects ; Genomes ; HA protein ; HA2 stalk region antibody ; Health aspects ; Hemagglutinins ; Immunosurveillance ; Influenza A ; Influenza virus ; Influenza viruses ; Lethal dose ; Lymphocytes ; Membranes ; Molecular diagnostic techniques ; Monoclonal antibodies ; Pandemics ; Plasmids ; Proteins ; Public health ; Vaccines ; Viral proteins ; Virus research ; Viruses</subject><ispartof>Virology journal, 2020-12, Vol.17 (1), p.191-191, Article 191</ispartof><rights>COPYRIGHT 2020 BioMed Central Ltd.</rights><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c548t-aab71f54b330af94ddd73775beec4d289ce328c5ed1a63379572a747c8b22f253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720065/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2471211988?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33287849$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Jingjin</creatorcontrib><creatorcontrib>Huang, Nan</creatorcontrib><creatorcontrib>Fan, Menglu</creatorcontrib><creatorcontrib>Zhao, Lingcai</creatorcontrib><creatorcontrib>Luo, Yan</creatorcontrib><creatorcontrib>Ding, Pingyun</creatorcontrib><creatorcontrib>Tian, Miao</creatorcontrib><creatorcontrib>Liu, Qingzheng</creatorcontrib><creatorcontrib>Guo, Yanna</creatorcontrib><creatorcontrib>Zhao, Jinhua</creatorcontrib><creatorcontrib>Zheng, Yiqing</creatorcontrib><creatorcontrib>Zhang, Haitao</creatorcontrib><creatorcontrib>Ping, Jihui</creatorcontrib><title>Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus</title><title>Virology journal</title><addtitle>Virol J</addtitle><description>Influenza virus remains a continuous and severe threat to public health worldwide, and its prevention and treatment have always been a major international issue. Because of its ability to evade immune surveillance through rapid antigenic drift and antigenic shift, broad-spectrum vaccines seem increasingly important.
A mAb named 3C12 from an immortalized hybrid cell was generated via immunizing mice with HA2 protein from A/chicken/Anhui/BRI99/2016 (AH/BRI99/16, H9N2) generated by prokaryotic expression. Then, its broad-spectrum activity was analyzed by WB and IFA. Next, the minimal linear epitope was identified via analyzing the reaction of a series of HA truncations with 3C12. Finally, the protective effects of 3C12 were evaluated in vitro and in vivo infection experiments.
The mAb could react with the viruses of subtypes H1, H2, H5, H8, H9, H12, H13, H16, and HA protein of H18 in group 1, but failed to react with viruses in group 2. The minimal linear epitope targeted by the mAb was
NAELLVL
in full length of HA and localized in the C-helix region of HA2 (residue 95-101, HA2 numbering). What's more, the mAb 3C12 inhibited H1, H2, H5, H8, H9, H12, H13 and H16 virus-replication in vitro and also has shown effectiveness in preventing and treating disease in mice challenged with lethal dose of AH/BRI99/16 (H9N2) virus in vivo. These results suggested that the broadly reactive anti-HA stem mAb 3C12 exhibited prophylactic and therapeutic efficacy.
Here, we have demonstrated that the linear epitope identified in this study could be a novel target for developing broad-spectrum influenza diagnostics or vaccine design, and the HA2-based monoclonal antibody is indeed a promising strategy for broad-spectrum protection against seasonal and pandemic influenza viruses.</description><subject>Antigenic drift</subject><subject>Avian flu</subject><subject>Broad-spectrum</subject><subject>Epitope</subject><subject>Epitopes</subject><subject>Genetic aspects</subject><subject>Genomes</subject><subject>HA protein</subject><subject>HA2 stalk region antibody</subject><subject>Health aspects</subject><subject>Hemagglutinins</subject><subject>Immunosurveillance</subject><subject>Influenza A</subject><subject>Influenza virus</subject><subject>Influenza viruses</subject><subject>Lethal dose</subject><subject>Lymphocytes</subject><subject>Membranes</subject><subject>Molecular diagnostic techniques</subject><subject>Monoclonal antibodies</subject><subject>Pandemics</subject><subject>Plasmids</subject><subject>Proteins</subject><subject>Public health</subject><subject>Vaccines</subject><subject>Viral proteins</subject><subject>Virus research</subject><subject>Viruses</subject><issn>1743-422X</issn><issn>1743-422X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl2L1DAUhoso7jr6B7yQgjd60TVfTdobYVjUHVgQ_ADvwmmS1oxpMybp4MyvN7OzrjsiuUg4ec57kpe3KJ5jdIFxw99ETNqmrhBBFcKsbqr9g-IcC0YrRsi3h_fOZ8WTGNcIUcJF-7g4o5Q0omHtebG-MiMMg5uTnexUxgTuR9VBNLoc_eSV8xO4EqZkO693pXFW2RTLLnjQblcGAyrZrU27EgawU0zlEPy8KXFpp97NZtpDuSy3NszxafGoBxfNs9t9UXx9_-7L5VV1_fHD6nJ5XamaNakC6ATua9ZRiqBvmdZaUCHqzhjFNGlaZfLrVW00Bk6paGtBQDChmo6QntR0UayOutrDWm6CHSHspAcrbwo-DBJCssoZWaNOG01axnnPOAXgDPGe9oIchme_FsXbo9Zm7kajlZlSAHcienoz2e9y8FspBEGIHx7z6lYg-J-ziUmONirjHEzGz1ESxhtKeWYz-vIfdO3nkO0_UAITjNum-UsNkD-QTfZ5rjqIyiWvEcctaXCmLv5D5aXNaJWfTG9z_aTh9UlDZpL5lQaYY5Srz59OWXJkVfAxBtPf-YGRPCRTHpMpczLlTTLlPje9uO_kXcufKNLf1E3eeA</recordid><startdate>20201207</startdate><enddate>20201207</enddate><creator>Huang, Jingjin</creator><creator>Huang, Nan</creator><creator>Fan, Menglu</creator><creator>Zhao, Lingcai</creator><creator>Luo, Yan</creator><creator>Ding, Pingyun</creator><creator>Tian, Miao</creator><creator>Liu, Qingzheng</creator><creator>Guo, Yanna</creator><creator>Zhao, Jinhua</creator><creator>Zheng, Yiqing</creator><creator>Zhang, Haitao</creator><creator>Ping, Jihui</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20201207</creationdate><title>Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus</title><author>Huang, Jingjin ; Huang, Nan ; Fan, Menglu ; Zhao, Lingcai ; Luo, Yan ; Ding, Pingyun ; Tian, Miao ; Liu, Qingzheng ; Guo, Yanna ; Zhao, Jinhua ; Zheng, Yiqing ; Zhang, Haitao ; Ping, Jihui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c548t-aab71f54b330af94ddd73775beec4d289ce328c5ed1a63379572a747c8b22f253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antigenic drift</topic><topic>Avian flu</topic><topic>Broad-spectrum</topic><topic>Epitope</topic><topic>Epitopes</topic><topic>Genetic aspects</topic><topic>Genomes</topic><topic>HA protein</topic><topic>HA2 stalk region antibody</topic><topic>Health aspects</topic><topic>Hemagglutinins</topic><topic>Immunosurveillance</topic><topic>Influenza A</topic><topic>Influenza virus</topic><topic>Influenza viruses</topic><topic>Lethal dose</topic><topic>Lymphocytes</topic><topic>Membranes</topic><topic>Molecular diagnostic techniques</topic><topic>Monoclonal antibodies</topic><topic>Pandemics</topic><topic>Plasmids</topic><topic>Proteins</topic><topic>Public health</topic><topic>Vaccines</topic><topic>Viral proteins</topic><topic>Virus research</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Jingjin</creatorcontrib><creatorcontrib>Huang, Nan</creatorcontrib><creatorcontrib>Fan, Menglu</creatorcontrib><creatorcontrib>Zhao, Lingcai</creatorcontrib><creatorcontrib>Luo, Yan</creatorcontrib><creatorcontrib>Ding, Pingyun</creatorcontrib><creatorcontrib>Tian, Miao</creatorcontrib><creatorcontrib>Liu, Qingzheng</creatorcontrib><creatorcontrib>Guo, Yanna</creatorcontrib><creatorcontrib>Zhao, Jinhua</creatorcontrib><creatorcontrib>Zheng, Yiqing</creatorcontrib><creatorcontrib>Zhang, Haitao</creatorcontrib><creatorcontrib>Ping, Jihui</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Virology journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Jingjin</au><au>Huang, Nan</au><au>Fan, Menglu</au><au>Zhao, Lingcai</au><au>Luo, Yan</au><au>Ding, Pingyun</au><au>Tian, Miao</au><au>Liu, Qingzheng</au><au>Guo, Yanna</au><au>Zhao, Jinhua</au><au>Zheng, Yiqing</au><au>Zhang, Haitao</au><au>Ping, Jihui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus</atitle><jtitle>Virology journal</jtitle><addtitle>Virol J</addtitle><date>2020-12-07</date><risdate>2020</risdate><volume>17</volume><issue>1</issue><spage>191</spage><epage>191</epage><pages>191-191</pages><artnum>191</artnum><issn>1743-422X</issn><eissn>1743-422X</eissn><abstract>Influenza virus remains a continuous and severe threat to public health worldwide, and its prevention and treatment have always been a major international issue. Because of its ability to evade immune surveillance through rapid antigenic drift and antigenic shift, broad-spectrum vaccines seem increasingly important.
A mAb named 3C12 from an immortalized hybrid cell was generated via immunizing mice with HA2 protein from A/chicken/Anhui/BRI99/2016 (AH/BRI99/16, H9N2) generated by prokaryotic expression. Then, its broad-spectrum activity was analyzed by WB and IFA. Next, the minimal linear epitope was identified via analyzing the reaction of a series of HA truncations with 3C12. Finally, the protective effects of 3C12 were evaluated in vitro and in vivo infection experiments.
The mAb could react with the viruses of subtypes H1, H2, H5, H8, H9, H12, H13, H16, and HA protein of H18 in group 1, but failed to react with viruses in group 2. The minimal linear epitope targeted by the mAb was
NAELLVL
in full length of HA and localized in the C-helix region of HA2 (residue 95-101, HA2 numbering). What's more, the mAb 3C12 inhibited H1, H2, H5, H8, H9, H12, H13 and H16 virus-replication in vitro and also has shown effectiveness in preventing and treating disease in mice challenged with lethal dose of AH/BRI99/16 (H9N2) virus in vivo. These results suggested that the broadly reactive anti-HA stem mAb 3C12 exhibited prophylactic and therapeutic efficacy.
Here, we have demonstrated that the linear epitope identified in this study could be a novel target for developing broad-spectrum influenza diagnostics or vaccine design, and the HA2-based monoclonal antibody is indeed a promising strategy for broad-spectrum protection against seasonal and pandemic influenza viruses.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>33287849</pmid><doi>10.1186/s12985-020-01458-z</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1743-422X |
ispartof | Virology journal, 2020-12, Vol.17 (1), p.191-191, Article 191 |
issn | 1743-422X 1743-422X |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_50bded29466f463aa6406f3f72330a00 |
source | Publicly Available Content Database; PubMed Central |
subjects | Antigenic drift Avian flu Broad-spectrum Epitope Epitopes Genetic aspects Genomes HA protein HA2 stalk region antibody Health aspects Hemagglutinins Immunosurveillance Influenza A Influenza virus Influenza viruses Lethal dose Lymphocytes Membranes Molecular diagnostic techniques Monoclonal antibodies Pandemics Plasmids Proteins Public health Vaccines Viral proteins Virus research Viruses |
title | Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T18%3A54%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hemagglutinin%20stalk-based%20monoclonal%20antibody%20elicits%20broadly%20reactivity%20against%20group%201%20influenza%20A%20virus&rft.jtitle=Virology%20journal&rft.au=Huang,%20Jingjin&rft.date=2020-12-07&rft.volume=17&rft.issue=1&rft.spage=191&rft.epage=191&rft.pages=191-191&rft.artnum=191&rft.issn=1743-422X&rft.eissn=1743-422X&rft_id=info:doi/10.1186/s12985-020-01458-z&rft_dat=%3Cgale_doaj_%3EA650619281%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c548t-aab71f54b330af94ddd73775beec4d289ce328c5ed1a63379572a747c8b22f253%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2471211988&rft_id=info:pmid/33287849&rft_galeid=A650619281&rfr_iscdi=true |